Talphera beats EPS expectations on 50% enrollment milestone
Biotech raises 2026 guidance to fund NEPHRO CRRT trial completion as PMA filing looms
Talphera shares slipped below key moving averages on Monday despite the biotechnology company reporting better-than-expected fourth-quarter results and reaching a critical enrollment milestone in its flagship clinical study.
The San Mateo-based company reported a net loss of $3.8 million, or 6 cents per share, for the quarter ended December 31, 2025, according to a regulatory filing. That represented a 52% improvement over the consensus estimate of a 12.5-cent loss, though the quarterly loss widened from $1.9 million in the same period a year earlier.
The more significant development for investors came on the clinical front, where Talphera announced it has enrolled 35 of 70 planned patients in its NEPHRO CRRT registrational study, reaching the 50% milestone with all 12 clinical sites now active. The trial is evaluating Niyad™, the company's regional anticoagulant therapy designed for continuous renal replacement therapy.
The enrollment acceleration follows strategic changes implemented in 2025, including a nearly 60% reduction in total patient requirements agreed to by the FDA, along with revised enrollment criteria. The company refocused its clinical site target profile on medical intensive care units and recruited nephrologists as principal investigators, changes that have positively impacted enrollment rates, according to the announcement.
"We are pleased to have reached this important enrollment milestone and remain on track for study completion and PMA filing later this year," the company stated in the press release.
Talphera expects to file a Premarket Approval application with the FDA in 2026, aiming to position Niyad™ as the only FDA-approved regional anticoagulant for CRRT—a significant unmet need in critical care medicine. The company hosted a virtual investor and analyst event on March 23 featuring nephrologists Dr. Blaithin McMahon and Dr. Joao Teixeira, principal investigators in the study, to discuss the clinical landscape.
To fund the trial's completion and regulatory filing, Talphera raised its 2026 operating expense guidance to $17-18 million, up from approximately $13 million in 2025. The increased spending reflects costs associated with the NEPHRO CRRT study and related chemistry, manufacturing, and control expenses for validation batches ahead of the PMA submission.
The company ended 2025 with $20.4 million in cash and investments, bolstered by a $4.1 million financing tranche closed in March 2026. Talphera reported combined research and development and selling, general, and administrative expenses of $3.5 million in the fourth quarter, up from $3.0 million in the prior-year period, primarily driven by Niyad development costs.
Despite these positive developments, Talphera's stock faces headwinds. The shares are trading below both their 50-day moving average of 90 cents and 200-day moving average of 86 cents, according to market data. The stock gained 2.99% on Friday to close at 83 cents, giving the company a market capitalization of approximately $38.8 million.
The company received a Nasdaq minimum bid-price deficiency notice on March 13, adding pressure to regain compliance with the exchange's $1.00 minimum bid requirement. The stock has traded in a 52-week range of 38 cents to $1.57.
Analysts remain optimistic on the company's prospects despite the current trading weakness. One analyst maintains a "Strong Buy" rating with a $6 price target, representing more than 600% upside from current levels, while consensus data shows a target of $3.25. Institutional investors own approximately 43% of shares, while insiders hold 26.5%.
Talphera's TTM revenue remains minimal at $28,000, with a trailing twelve-month net loss of $13.0 million as of the most recent data. The company's book value stands at 42 cents per share, with a price-to-book ratio of 2.02.
The NEPHRO CRRT study completion and subsequent PMA filing in 2026 represent the primary catalysts for the stock, with the outcome likely determining whether Talphera can overcome its current market challenges and achieve analyst expectations.